A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression

Pancreatology

Volumn 14, Issue 5, 2014, Pages 398-402

  Li, D ^a   Pant, S ^b   Ryan, D P ^c   Laheru, D ^d   Bahary, N ^e   Dragovich, T ^f   Hosein, P J ^g   Rolfe, L ^h   Saif, M W ⁱ   Lavalle, J ^a   Yu, K H ^a   Lowery, M A ^a   Allen, A ^h   O'Reilly, E M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Peggy and Charles Stephenson Oklahoma Cancer Institute   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UNIVERSITY OF MIAMI   (United States)

^h Clovis Oncology Inc   (United States)

ⁱ Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Biomarker; CO 1.01; Disease control rate; Gemcitabine refractory; hENT1; Pancreas adenocarcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; GEMCITABINE ELAIDATE; IMMUNOLOGIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; SLC29A1 PROTEIN, HUMAN; TUMOR MARKER;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; ASCITES; ASTHENIA; BACKACHE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHOLANGITIS; CLINICAL ARTICLE; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GENE EXPRESSION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOTENSION; LEUKOPENIA; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PATIENT ASSESSMENT; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; SEPSIS; SPINE FRACTURE; SURVIVAL TIME; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84908251517     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2014.07.003     Document Type: Article

References (22)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. H.A. Burris, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, and M.R. Modiano Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
3. C. Louvet, R. Labianca, P. Hammel, G. Lledo, M.G. Zampino, and T. Andre Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 2005 3509 3516
4. D.D. Von Hoff, T.J. Ervin, F.P. Arena, G.E. Chiorean, J.R. Infante, and M.J. Moore Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT) JCO 31 2013 [suppl abstr 148]
5. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, and Y. Becouarn FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
6. A. Custodio, J. Puente, J. Sastre, and E. Díaz-Rubio Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions Cancer Treat Rev 35 2009 676 684
7. O.E. Rahma, A. Duffy, D.J. Liewehr, S.M. Steinberg, and T.F. Greten Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials Ann Oncol 00 2013 1 8
8. V.L. Damaraju, M.B. Sawyer, J.R. Mackey, J.D. Young, and C.E. Cass Human nucleoside transporters: biomarkers for response to nucleoside drugs Nucleos Nucleot Nucl 5 2009 450 463
9. J.R. Mackey, R.S. Mani, M. Selner, D. Mowles, J.D. Young, and J.A. Belt Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res 58 1998 4349 4357
10. J.J. Farrell, H. Elsaleh, M. Garcia, R. Lai, A. Ammar, and W.F. Regine Human ENT1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology 136 2009 187 195
11. W.F. Regine, K.A. Winter, R.A. Abrams, H. Safran, J.P. Hoffman, and A. Konski Fluorouracil versus gemcitabine chemotherapy before and after fluorouracil-based chemoradiation after resection of pancreatic adenocarcinoma. A randomized controlled trail JAMA 299 2008 1019 1026
12. E. Giovannetti, M. Del Tacca, V. Mey, N. Funel, S. Nannizzi, and S. Ricci Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine Cancer Res 66 2006 3928 3935
13. J. Spratlin, R. Sangha, D. Glubrecht, L. Dabbagh, J.D. Young, and C. Dumontet The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clin Cancer Res 10 2004 6956 6961
14. J.P. Neoptolemos, W. Greenhalf, P. Ghaneh, D.H. Palmer, T.F. Cox, and E. Garner HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials JCO 31 2013 [suppl abstr 4006]
15. J.P. Neoptolemos, D.D. Stocken, H. Friess, C. Bassi, J.A. Dunn, and H. Hickey A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200 1210
16. J.P. Neoptolemos, D.D. Stocken, C. Bassi, P. Ghaneh, D. Cunningham, and D. Goldstein Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 2010 1073 1081
17. R. Simon Optimal two stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
18. A. Demols, M. Peeters, M. Polus, R. Marechai, F. Gay, and E. Monsaert Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 2006 481 485
19. H.Q. Xiong, G.R. Varadhachary, J.C. Blais, K.R. Hess, J.L. Abbruzzese, and R.A. Wolff Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer Cancer 113 2008 2046 2052
20. U. Pelzer, I. Schwaner, J. Stieler, M. Adler, J. Seraphin, and B. Dorken Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group Eur J Cancer 47 2011 1676 1681
21. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
22. E. Poplin, H. Wasan, L. Rolfe, M. Raponi, T. Ikdahl, and I. Bondarenko Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma and a prospective evaluation of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment JCO 31 2013 [suppl abstr 4007]